ClinicalTrials.gg
RecruitingNCT07213466OBOE-MayoUpdated Mar 11, 2026

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

A Phase 4 interventional study of Group Therapy Program and semaglutide in Bipolar I Disorder, Bipolar II Disorder and Schizo Affective Disorder, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment

How we know · 12 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Bipolar Disorder by Mayo Clinic — 5 open to participants now, 6 under way, none of them phase 3. Bipolar Disorder · Mayo Clinic.

Planned enrollment
2nd of 12
100 · median 35
Started
2026
with 2 others
Phase 4
5 of 13
2 open now
Registered
11th of 13
by date

Among the 13 studies in Bipolar Disorder by Mayo Clinic, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 4, and was the 11th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

5 of the 13 studies in Bipolar Disorder by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Bipolar Disorder by Mayo Clinic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in patients with bipolar disorder ages 18-65. The main questions it aims to answer are:

  • Can the investigators compare the distribution of obesity characteristics (hungry brain, hungry gut, emotional hunger) between bipolar patients and non-bipolar participants (comparing from IRB #24-002375)?
  • Can the investigators evaluate the feasibility of anti-obesity medication (AOM) in patients with bipolar disorder?

Participation will last for about 20 weeks and includes 8 in-person study visits, up to 11 phone call visits, and 13 virtual group therapy sessions. The first visit lasts about 2 hours and includes going over the informed consent form, a diagnostic interview to confirm diagnosis, gathering vital signs, mood questionnaires, an ECG, a blood draw, and urine drug and pregnancy tests (if applicable). The second visit lasts about 6-7 hours and involves multiple procedures and completing questionnaires to determine which study drug would allow participants to lose weight most effectively. At the third visit, participants will be assigned to take one of three FDA approved medications for weight loss: Semaglutide (Wegovy®), Naltrexone/Bupropion (Contrave®), or Phentermine/Topiramate (Qsymia®). It is possible that participants could be assigned to a group that receives no study medication. All participants will be enrolled in a 12-week virtual group therapy program targeted for weight loss. On this third visit the investigators will also gather vital signs, and participants will give a sample of blood. After the third visit, participants will come in for study visits every 4 weeks for 20 weeks (5 visits) to assess medication adherence, vitals, and answer questions about mood and eating (participants will also give a sample of blood at the 8-week and 20-week visits). For participants assigned to a study medication, the study team will call every week for the first 2 months (excluding in-person visit weeks) to assess mood and safety. After the first 2 months, the study team will call the participant every two weeks in between in-person visits. Participants will be compensated for time spent in this study. Participants assigned to a study medication will also be given the option to participate in the open-label phase of the study, which involves 3 follow-up visits (weeks 24, 36, and 48) over 7 months after the 20-week trial. During this phase, participants can continue to take the medication through their clinical care provider.

Read the detailed description

This is a single-site, open-label, non-randomized interventional pilot study evaluating a phenotype-guided pharmacological approach to obesity in adults with bipolar disorder (BD). The study aims to assess the distribution of obesity phenotypes and the efficacy, safety, and tolerability of individualized anti-obesity pharmacotherapy in this population. A total of 100 participants with BD and comorbid obesity will be enrolled and stratified into one of four obesity phenotypes: Hungry Brain (abnormal satiation), Hungry Gut (abnormal postprandial satiety), Emotional Hunger (emotional eating), and Slow Burn (low resting energy expenditure).

Participants will undergo comprehensive obesity phenotyping, including indirect calorimetry, gastric emptying scintigraphy, DEXA scans, ad libitum buffet meal testing, and validated behavioral questionnaires. Based on phenotype classification, participants will receive one of the following FDA-approved anti-obesity medications (AOMs): phentermine-topiramate ER (Qsymia®), semaglutide (Wegovy®), or naltrexone-bupropion ER (Contrave®). Participants with the Slow Burn phenotype will receive behavioral and lifestyle interventions only.

All participants will engage in a 12-week virtual behavioral intervention program led by a multidisciplinary team, including a psychologist and a registered dietitian. The program includes weekly group sessions focused on nutrition, physical activity, cognitive restructuring, and relapse prevention.

A comprehensive data safety monitoring plan (DSMP) is in place, including bi-monthly reviews by a multidisciplinary team. Adverse events (AEs) and serious adverse events (SAEs) will be monitored and reported per institutional and federal guidelines. Participants will be withdrawn from the study if they experience treatment-emergent mania, severe depression, suicidality, or other safety concerns.

The statistical analysis plan includes descriptive statistics, repeated measures models, and subgroup analyses by phenotype and BD subtype. Missing data will be handled using multiple imputation or maximum likelihood methods. No formal multiplicity adjustments will be applied due to the exploratory nature of the study.

This study addresses a critical gap in obesity treatment for individuals with serious mental illness by integrating precision medicine with psychiatric care. The findings will inform future randomized controlled trials and contribute to the development of personalized obesity interventions in psychiatric populations.

03

Conditions studied

  • Bipolar I Disorder
  • Bipolar II Disorder
  • Schizo Affective Disorder
  • Obesity
  • Weight Loss
  • GLP - 1
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women between 18 to 65 years old.
  • Patients with a SCID IV confirmed diagnosis of bipolar disorder (BDI or BDII) or schizoaffective bipolar type (SZA-BD).
  • Women with a negative pregnancy test 48 hours before study entry (obesity phenotyping visit).
  • Patients with a negative urine drug screen except for allowable drugs.
  • Patients with a ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 plus one medical comorbidity (e.g., type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
  • Patients must be undergoing mood stabilizer treatment but may also receive concurrent antidepressant or anxiolytic therapy.
  • Patients must be on a stable regimen of a mood stabilizer, with no changes to the medication, for at least one month prior to study enrollment.
  • Continuation of mood-stabilizing treatment is preferred but not required; the decision should be made in collaboration with the participant's primary mental health provider.

Exclusion criteria

Exclusion Criteria:

  • Abdominal bariatric surgery: Gastric bypass surgery (Roux-en-Y), Adjustable gastric band (Lap band), and Gastric sleeve surgery (Sleeve gastrectomy).
  • Positive history of chronic gastrointestinal diseases, or systemic disease that could affect gastrointestinal motility, such as diabetic gastroparesis; or use of medications that may alter gastrointestinal motility and appetite.
  • Positive history of chronic gastrointestinal diseases that could affect gastrointestinal absorption such as inflammatory bowel disease (IBD), celiac disease, small intestinal bacterial overgrowth (SIBO), etc; or use of medications that may alter gastrointestinal absorption.
  • Significant untreated psychiatric dysfunction.
  • to any of the study medications.
  • to the FDA-approved medications: Phentermine-Topiramate Extended Release; Oral naltrexone extended-release/bupropion extended-release (NBSR; Contrave®, Mysimba™); and Semaglutide (Weygovy™).
  • Inability to provide : participants who are on involuntary commitment, conservatorship or under a legal guardian.
  • Patients with active hypomania or mania (YMRS ≥ 20 points)
  • Patients with active psychosis (YMRS item 8 ≥ 6 points)
  • Patients with active suicide ideation (MADRS item 10 ≥ 4 points)
  • Patients with any medication changes (mood stabilizers) without advisement of study clinicians or clinical provider.
  • Patients with active bulimia (purging) or anorexia (severe restriction)
  • Patients with a history of bulimia (purging behaviors) or anorexia (severe dietary restriction) within the 12 months preceding study enrollment will be excluded
  • Current drug and/or alcohol use disorders (except nicotine)
  • Patients with a positive toxicology screening (except cannabis)
  • Positive toxicology screen for cannabis and a cannabis use disorder by CUDIT-R.
  • Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less.
  • Patients unwilling to complete the full phenotyping day on its current form (i.e. patients avoiding gluten meal or adhering to a vegan diet).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Semaglutide (Wegovy) + Group Therapy Program

    By meeting the satiety/return to hunger (Hungry Gut) phenotype, participants will take Semaglutide (Wegovy) and attend a 12-week group therapy session for the 16-week clinical trial.

    Behavioral: Group Therapy Program · Drug: semaglutide

  • Experimental
    Naltrexone/Bupropion (Contrave) + Group Therapy Program

    By meeting the behavioral/psychological (Emotional Hunger) phenotype, participants will take Naltrexone/Bupropion (Contrave) and attend a 12-week group therapy session for the 16-week clinical trial.

    Behavioral: Group Therapy Program · Drug: naltrexone and bupropion (combination)

  • Experimental
    Phentermine/Topiramate (Qsymia) + Group Therapy Program

    By meeting the satiation (Hungry Brain) phenotype, participants will take Phentermine/Topiramate (Qsymia) and attend a 12-week group therapy session for the 16-week clinical trial.

    Behavioral: Group Therapy Program · Drug: Phentermine-Topiramate

  • Experimental
    No Study Medication + Group Therapy Program

    By meeting the slow burn phenotype, participants will attend a 12-week group therapy session for the 16-week clinical trial.

    Behavioral: Group Therapy Program

Interventions

06

What researchers measure

Primary outcomes

  1. Describe the distribution of obesity phenotypes (hungry brain, hungry gut, emotional hunger and slow burn) in patients with BD and obesity, with the goal of identifying predominant phenotype patterns within this clinical population.

    Time frame: From enrollment through the end of the 20-week intervention.

Secondary outcomes

  1. Compare the distribution of obesity phenotypes (hungry brain, hungry gut, emotional hunger, and slow burn) in patients with BD and obesity and non-BD participants published in previously cohorts.

    Time frame: From the start of intervention (week 0) through the end of intervention (week 20).

  2. The feasibility and tolerability of anti-obesity medication (AOM) in patients with BD, assessed by adherence rates and reports on adverse events.

    Time frame: from the start of intervention (week 0) through the end of intervention (week 20).

  3. Total body weight loss (in kilograms) from baseline to end point in patients with BD and obesity.

    Time frame: From the start of intervention (week 0) through the end of intervention (week 20).

  4. The proportion of treatment responders, defined as individuals achieving >4% total body weight loss, from baseline to end point in patients with BD and obesity.

    Time frame: From the start of intervention (week 0) through the end of intervention (week 20).

  5. Changes in metabolic parameters from baseline to end point in patients with BD.

    Time frame: From the start of intervention (week 0) through the end of intervention (week 20).

  6. Changes in eating behavior from baseline to endpoint in patients with BD using validated questionnaires.

    Time frame: From the start of intervention (week 0) through the end of intervention (week 20).

  7. Changes in mood symptoms from baseline to endpoint in patients with BD using validated questionnaires.

    Time frame: From the start of intervention (week 0) through the end of intervention (week 20).

Other outcomes

  1. Changes in mitochondrial biomarkers from baseline to end point in patients with BD and obesity.

    Time frame: From the start of intervention (week 0) through the end of intervention (week 20)

  2. Changes in stress related biomarkers from baseline to end point in patients with BD and obesity.

    Time frame: From the start of intervention (week 0) through the end of intervention (week 20)

  3. Surrogate biomarkers of obesity phenotypes.

    Time frame: From the start of intervention (week 0) through the end of intervention (week 20).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.

Of 39 non-industry phase 4 interventional studies under Bipolar Disorder, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 24 months is below that.

Counting every sponsor, half of 44 studies reached it within 43 months; a quarter within 25 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Oct 9, 2025
StartActual
Jan 19, 2026
Primary completionEst.
Feb 1, 2028
CompletionEst.
Feb 1, 2029
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07213466
Lead sponsor
Mayo Clinic
Responsible party
Mark Frye (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Oct 9, 2025
Start date
Jan 19, 2026
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Mar 11, 2026

Study contacts

Laura N Harper
Contact
harper.laura1@mayo.edu
507-255-9352
Karin M Lindstrom, Ph.D.
Contact
lindstrom.karin@mayo.edu
507-293-3876
Mark A Frye, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Semaglutide · Phentermine · Topiramate · Naltrexone · Bupropion

Start the discussion